[go: up one dir, main page]

AR103415A1 - Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 - Google Patents

Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2

Info

Publication number
AR103415A1
AR103415A1 ARP160100087A ARP160100087A AR103415A1 AR 103415 A1 AR103415 A1 AR 103415A1 AR P160100087 A ARP160100087 A AR P160100087A AR P160100087 A ARP160100087 A AR P160100087A AR 103415 A1 AR103415 A1 AR 103415A1
Authority
AR
Argentina
Prior art keywords
treatment
type
pediatric patients
mellitus diabetes
lixisenatide
Prior art date
Application number
ARP160100087A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52354814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR103415(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR103415A1 publication Critical patent/AR103415A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Lixisenatida para su uso en pacientes pediátricos. Reivindicación 2: Lixisenatida o/y una sal ,farmacéuticamente aceptable de la misma, para su uso según la reivindicación 1, en la que la lixisenatida o/y la sal farmacéuticamente aceptable de la misma se administra como una terapia adicional a metformina o/y una sal farmacéuticamente aceptable de la misma.
ARP160100087A 2015-01-16 2016-01-14 Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 AR103415A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15151488 2015-01-16

Publications (1)

Publication Number Publication Date
AR103415A1 true AR103415A1 (es) 2017-05-10

Family

ID=52354814

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100087A AR103415A1 (es) 2015-01-16 2016-01-14 Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2

Country Status (21)

Country Link
US (4) US20160235818A1 (es)
EP (1) EP3244912B1 (es)
JP (1) JP7274258B2 (es)
KR (1) KR102614574B1 (es)
CN (1) CN107405386A (es)
AR (1) AR103415A1 (es)
AU (1) AU2016207964B2 (es)
CL (1) CL2017001843A1 (es)
CR (1) CR20170376A (es)
EA (1) EA035423B1 (es)
ES (1) ES2895513T3 (es)
IL (1) IL253460B (es)
MX (1) MX381944B (es)
PH (1) PH12017501290A1 (es)
PL (1) PL3244912T3 (es)
PT (1) PT3244912T (es)
SG (1) SG11201705755UA (es)
TN (1) TN2017000292A1 (es)
TW (1) TWI706779B (es)
WO (1) WO2016113404A1 (es)
ZA (1) ZA201704512B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
DE102019129444A1 (de) * 2019-10-31 2021-05-06 Lts Lohmann Therapie-Systeme Ag Lagtime-Verkürzung/Eisspray
US20240260559A1 (en) * 2021-04-11 2024-08-08 Vikas Khurana Device and process for trapping and compressing organisms
WO2024133412A1 (en) 2022-12-21 2024-06-27 Novo Nordisk A/S Methods and systems for estimating fbg value from cgm data

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AR075204A1 (es) * 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
EP2435061A4 (en) * 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
ES2553593T3 (es) * 2009-11-13 2015-12-10 Sanofi-Aventis Deutschland Gmbh Lixisenatida como complemento de la metformina en el tratamiento de la diabetes tipo 2
CN103841988A (zh) * 2011-05-13 2014-06-04 赛诺菲-安万特德国有限公司 用于治疗2型糖尿病患者的利西拉来和二甲双胍
US9821032B2 (en) * 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013003449A2 (en) * 2011-06-27 2013-01-03 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
HRP20151068T1 (hr) * 2011-08-29 2016-01-01 Sanofi-Aventis Deutschland Gmbh Farmaceutska kombinacija za upotrebu za glikemijsku kontrolu kod pacijenata s dijabetesom tipa 2
US20130296236A1 (en) * 2011-10-28 2013-11-07 Louise SILVESTRE Treatment protocol of diabetes type 2

Also Published As

Publication number Publication date
KR102614574B1 (ko) 2023-12-18
US20240173384A1 (en) 2024-05-30
EA201791611A1 (ru) 2017-11-30
IL253460A0 (en) 2017-09-28
BR112017015099A2 (pt) 2018-04-17
KR20170102550A (ko) 2017-09-11
CN107405386A (zh) 2017-11-28
IL253460B (en) 2022-06-01
ZA201704512B (en) 2019-07-31
TN2017000292A1 (en) 2019-01-16
CR20170376A (es) 2017-09-25
AU2016207964B2 (en) 2021-10-14
CA2973632A1 (en) 2016-07-21
JP2018503644A (ja) 2018-02-08
SG11201705755UA (en) 2017-08-30
PT3244912T (pt) 2021-10-27
US20190365864A1 (en) 2019-12-05
TW201639551A (zh) 2016-11-16
CL2017001843A1 (es) 2018-02-23
PL3244912T3 (pl) 2021-12-20
JP7274258B2 (ja) 2023-05-16
EP3244912B1 (en) 2021-08-18
US20210187075A1 (en) 2021-06-24
US20160235818A1 (en) 2016-08-18
TWI706779B (zh) 2020-10-11
NZ734595A (en) 2022-03-25
MX381944B (es) 2025-03-13
WO2016113404A1 (en) 2016-07-21
PH12017501290A1 (en) 2018-02-05
ES2895513T3 (es) 2022-02-21
EP3244912A1 (en) 2017-11-22
MX2017009294A (es) 2017-11-20
AU2016207964A1 (en) 2017-08-31
EA035423B1 (ru) 2020-06-11

Similar Documents

Publication Publication Date Title
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
CL2015002940A1 (es) Usos terapéuticos de empaglifozina.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
DOP2012000299A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CL2012003197A1 (es) Formulación farmacéutica acuosa que comprende 200-1000 u/ml de insulina glargina, con condición de que la concentración de dicha formulación no sea 684 u/ml de insulina glargina; y su uso para tratar diabetes mellitus de tipo i y tipo ii en un paciente.
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
PH12018502593A1 (en) Combinations of linagliptin and metformin
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
MX389091B (es) Tratamiento de pacientes con diabetes mellitus de tipo 2.
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
MX2015014007A (es) Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de accion prolongada.
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CL2017002326A1 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
AR085998A1 (es) Aclidinio y su uso en la mejora de la calidad del sueño
UA100883C2 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
AR103944A1 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
CL2014003072A1 (es) Uso de un compuesto 2-((2r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida (veliparib o abt-888) o de una sal farmaceuticamente aceptable que sirve para el tratamiento de las metástasis en el cerebro con una combinación de una terapia con radiación en la totalidad del cerebro.
AR102978A1 (es) Formulación de relación fija de insulina glargina / lixisenatida

Legal Events

Date Code Title Description
FB Suspension of granting procedure